BR112017013936A2 - inibidores de bace1 seletivos. - Google Patents

inibidores de bace1 seletivos.

Info

Publication number
BR112017013936A2
BR112017013936A2 BR112017013936A BR112017013936A BR112017013936A2 BR 112017013936 A2 BR112017013936 A2 BR 112017013936A2 BR 112017013936 A BR112017013936 A BR 112017013936A BR 112017013936 A BR112017013936 A BR 112017013936A BR 112017013936 A2 BR112017013936 A2 BR 112017013936A2
Authority
BR
Brazil
Prior art keywords
bace1 inhibitors
selective bace1
selective
inhibitors
compound
Prior art date
Application number
BR112017013936A
Other languages
English (en)
Inventor
James Hembre Erik
Anne Mcmahon Jennifer
Eduardo Lopez Jose
Larry Winneroski Leonard Jr
James Richards Simon
Andrew Woods Timothy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112017013936A2 publication Critical patent/BR112017013936A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones

Abstract

a presente invenção provê um composto de fórmula ii: ou um seu sal farmaceuticamente aceitável.
BR112017013936A 2015-02-23 2016-02-17 inibidores de bace1 seletivos. BR112017013936A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119391P 2015-02-23 2015-02-23
PCT/US2016/018160 WO2016137788A1 (en) 2015-02-23 2016-02-17 Selective bace1 inhibitors

Publications (1)

Publication Number Publication Date
BR112017013936A2 true BR112017013936A2 (pt) 2018-01-02

Family

ID=55442893

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013936A BR112017013936A2 (pt) 2015-02-23 2016-02-17 inibidores de bace1 seletivos.

Country Status (27)

Country Link
US (1) US9522923B2 (pt)
EP (1) EP3262051B1 (pt)
JP (1) JP6111001B1 (pt)
KR (1) KR101945139B1 (pt)
CN (1) CN107257801B (pt)
AR (1) AR103680A1 (pt)
AU (1) AU2016223072B2 (pt)
BR (1) BR112017013936A2 (pt)
CA (1) CA2972098A1 (pt)
CL (1) CL2017002090A1 (pt)
CO (1) CO2017008382A2 (pt)
CR (1) CR20170315A (pt)
DO (1) DOP2017000178A (pt)
EA (1) EA031546B1 (pt)
EC (1) ECSP17054980A (pt)
GT (1) GT201700185A (pt)
IL (1) IL252969A0 (pt)
MX (1) MX367940B (pt)
NZ (1) NZ732940A (pt)
PE (1) PE20171337A1 (pt)
PH (1) PH12017501523A1 (pt)
SG (1) SG11201705764SA (pt)
SI (1) SI3262051T1 (pt)
TN (1) TN2017000355A1 (pt)
TW (1) TWI627177B (pt)
WO (1) WO2016137788A1 (pt)
ZA (1) ZA201704293B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US9938266B2 (en) 2015-03-19 2018-04-10 Eli Lilly And Company Selective BACE1 inhibitors
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3500296A1 (en) * 2016-08-18 2019-06-26 Eli Lilly and Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
ES2929667T3 (es) 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332005B (en) 2005-06-14 2010-10-21 Schering Corp Aspartyl protease inhibitors
CA2711655C (en) 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
JO3318B1 (ar) * 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos

Also Published As

Publication number Publication date
PE20171337A1 (es) 2017-09-13
PH12017501523A1 (en) 2018-02-05
MX367940B (es) 2019-09-12
IL252969A0 (en) 2017-08-31
NZ732940A (en) 2019-06-28
EA201791684A1 (ru) 2017-12-29
EP3262051A1 (en) 2018-01-03
EA031546B1 (ru) 2019-01-31
ECSP17054980A (es) 2017-11-30
CN107257801B (zh) 2019-08-13
DOP2017000178A (es) 2017-09-15
AU2016223072B2 (en) 2018-11-15
TWI627177B (zh) 2018-06-21
TW201643170A (zh) 2016-12-16
WO2016137788A1 (en) 2016-09-01
CO2017008382A2 (es) 2017-11-30
EP3262051B1 (en) 2019-10-02
CA2972098A1 (en) 2016-09-01
CN107257801A (zh) 2017-10-17
KR101945139B1 (ko) 2019-02-01
SI3262051T1 (sl) 2019-11-29
US20160244465A1 (en) 2016-08-25
MX2017010861A (es) 2017-12-11
US9522923B2 (en) 2016-12-20
AR103680A1 (es) 2017-05-24
CL2017002090A1 (es) 2018-04-13
SG11201705764SA (en) 2017-08-30
GT201700185A (es) 2018-11-23
ZA201704293B (en) 2019-01-30
JP2017511806A (ja) 2017-04-27
AU2016223072A1 (en) 2017-07-13
CR20170315A (es) 2017-08-14
KR20170103971A (ko) 2017-09-13
JP6111001B1 (ja) 2017-04-05
TN2017000355A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
BR112017013936A2 (pt) inibidores de bace1 seletivos.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
TW201613872A (en) IRAK4 inhibiting agents
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
EA201592183A1 (ru) Ингибиторы bace
DOP2018000042A (es) Antagonistas del receptor de cgrp
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
EA201791596A1 (ru) Пиразоловые соединения
UA107885U (uk) Застосування вінборону для профілактики гастропатії, індукованої ібупрофеном
TH168624B (th) อนุพันธ์กลูโคไพแรโนซิล-ซับสทิทิวเทด อินโดล-ยูเรีย และการใช้สารเหล่านั้น เป็นตัวยับยั้ง sglt

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements